28 August 2019 - Annual costs of disease modifying treatments for multiple sclerosis more than quadrupled from 2006 to 2016 as several new, costly medicines entered the market, a U.S. study suggests.

Before 2009, only four drugs were available to reduce symptoms and slow the progression of multiple sclerosIs (MS), a disabling autoimmune disease that damages the central nervous system and can lead to fatigue, pain, vision loss and impaired coordination and motor skills. Since 2009, seven new drugs have entered the U.S. market.

To assess shifts in costs after the debut of so many new medicines, researchers examined the annual cost of treatment for Medicare Part D drug plans based on doses of each injected medicine recommended by the U.S. Food and Drug Administration.

Read Reuters article